---
title: Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients
  With Primary Hyperoxaluria Type 1
date: '2024-02-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38312792/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240205170658&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: Lumasiran treatment is safe and efficient. Dosage (interval)
  adjustment necessities need clarification. In dialysis, lack of Pox reduction may
  relate to dissolving systemic oxalate deposits. Pglyc increment may be a considerable
  acid load requiring careful consideration, which definitively needs further ...'
disable_comments: true
---
CONCLUSION: Lumasiran treatment is safe and efficient. Dosage (interval) adjustment necessities need clarification. In dialysis, lack of Pox reduction may relate to dissolving systemic oxalate deposits. Pglyc increment may be a considerable acid load requiring careful consideration, which definitively needs further ...